Merck & Co., Inc. (MRK): Revenue
$65.01B
Year ended 2025-12-31
$66.57B
Trailing 12 months to 2026-06-30
+3.1%
3-year compound annual growth
+9.4%
5-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $65.01B | +1.3% | 2026-02-24, From 2025-01-01 |
| 2024-12-31 | $64.17B | +6.7% | 2026-02-24, From 2024-01-01 |
| 2023-12-31 | $60.12B | +1.4% | 2026-02-24, From 2023-01-01 |
| 2022-12-31 | $59.28B | +21.7% | 2025-02-25, From 2022-01-01 |
| 2021-12-31 | $48.70B | +17.3% | 2024-02-26, From 2021-01-01 |
| 2020-12-31 | $41.52B | +6.1% | 2023-02-24, From 2020-01-01 |
| 2019-12-31 | $39.12B | n/c | 2022-02-25, From 2019-01-01 |
| 2018-12-31 | $42.29B | +5.4% | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | $40.12B | +0.8% | 2020-02-26, From 2017-01-01 |
| 2016-12-31 | $39.81B | n/a | 2019-02-27, From 2016-01-01 |
| No annual figure between 2010-12-31 and 2016-12-31. | |||
| 2010-12-31 | $45.99B | +67.7% | 2011-02-28, From 2010-01-01 |
| 2009-12-31 | $27.43B | +15.0% | 2011-02-28, From 2009-01-01 |
| 2008-12-31 | $23.85B | -1.4% | 2011-02-28, From 2008-01-01 |
| 2007-12-31 | $24.20B | n/a | 2010-03-01, From 2007-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | 2025-12-31 | $65.01B | +1.3% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $65.18B | +44.7% |
| Pfizer Inc (PFE) | 2025-12-31 | $62.58B | -1.6% |
| AbbVie Inc. (ABBV) | 2025-12-31 | $61.16B | +8.6% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $48.19B | -0.2% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $94.19B | +6.0% |
| Abbott Laboratories (ABT) | 2025-12-31 | $44.33B | +5.7% |
| Teva Pharmaceutical Industries Ltd (TEVA) | 2025-12-31 | $17.26B | +4.3% |
| Regeneron Pharmaceuticals, Inc. (REGN) | 2025-12-31 | $14.34B | +1.0% |
Compare MRK, LLY, PFE, ABBV side by side · Screen every company in Pharmaceutical Preparations ↗